Kaitlin Christenson of the Global Health Technologies Coalition (GHTC), Jim Connolly of Aeras and Mel Spigelman of the TB Alliance write about the need for high-income countries to fund the development of new tuberculosis technologies for The Hill's Congress Blog.

The need for a global immunization program designed for the mass immunization of non-infant age groups with TB vaccines and formation of a new expert advisory committee on TB vaccines are two of the major recommendations by a panel of experts, announced January 6th by the World Health Organization in its Weekly Epidemiological Record.

‚ÄčThe positive news on malaria vaccine development announced this week has provided a boost to all of us who are working to develop new vaccines to fight infectious diseases that impact the poorest and most vulnerable communities.

Tuberculosis, vaccine and regulatory experts convened at a scientific symposium to discuss clinical development aspects of TB vaccine research in Bethesda, Maryland, on September 7, 2011. This event marked the second meeting on TB vaccine research of a new bi-annual symposium program co-sponsored by Aeras and the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health.

Greater political will needed to address TB vaccine development and future introduction challenges